Oct. 25, 2018
Amgen announced on Wednesday, Oct. 24 it is making evolocumab available at a reduced list price in an effort to improve affordability and access for patients.
The announcement represents positive news for patients at risk for cardiovascular events.
Key outcomes from Amgen’s FOURIER trial, revealed in March 2017, revealed evolocumab significantly reduced the risk of cardiovascular events and were supported by long-term safety data.
W. Virgil Brown, MD, FNLA and Ernst J. Schaefer, MD, FNLA, chairs of the Donald S. Fredrickson Conferences and Webinars on Familial Lipoprotein Disorders, are accepting case submissions for an upcoming webinar.
The deadline for submissions is Sunday, September 30. If a case is selected, the case submitter will be paired with one or several experts who will help them present and dissect your case in front of a live audience. The webinars will take place quarterly, and submissions may be considered for future webinars.
JACKSONVILLE, Fla. — Due to high demand, the rooming block at the Loews Vanderbilt Hotel in Nashville is sold out for the 2018 Fall Clinical Lipid Update.
Those planning to attend the Fall CLU are encouraged to explore other area hotels.
For additional information, visit lipid.org/fallclu.
Copyright © 2018 National Lipid Association. All Rights Reserved.
